http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Vertex Pharma (VRTX) Announces FDA Approval of TRIKAFTA
-
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
-
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
-
Vertex to Announce First Quarter 2023 Financial Results on May 1
-
Vertex Pharma (VRTX), CRISPR Therapeutics (CRSP) Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion
-
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Th
-
Vertex Pharma (VRTX), CRISPR Therapeutics (CRSP) Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
-
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
-
Vertex Pharma (VRTX) Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin
-
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
-
Vertex Pharma (VRTX) Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
-
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
-
Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7
-
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
-
Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
-
Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
-
Today's most important downgrades
-
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
-
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
-
Vertex Pharma (VRTX) , Entrada Therapeutics (TRDA) Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1
-
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
-
Vertex to Participate in Upcoming Investor Conferences
-
Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
-
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
-
Vertex Reports Third Quarter 2022 Financial Results
-
Vertex to Announce Third Quarter 2022 Financial Results on October 27
-
Vertex Pharma (VRTX) Advances Program Targeting Alpha-1 Antitrypsin Deficiency
-
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
-
Vertex Pharma (VRTX) and CRISPR (CRSP) Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia
-
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
-
Vertex Appoints Jonathan Biller as Chief Legal Officer
-
Vertex Pharma (VRTX) ORKAMBI Approved by FDA in Children With CF Ages 12 to <24 months
-
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
-
Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9
-
Vertex Reports Second Quarter 2022 Financial Results
-
Vertex Pharma (VRTX) to Advance VX-548 Study in Acute and Neuropathic Pain
-
Vertex Advances VX-548 in Acute and Neuropathic Pain
-
Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
-
Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
-
Vertex to Announce Second Quarter 2022 Financial Results on August 4
-
Vertex Pharma (VRTX) to Acquire ViaCyte for $320 Million
-
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
-
Vertex Pharma (VRTX) Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
-
Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
-
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
-
Vertex Pharma (VRTX) to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at ECFS
-
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
-
Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
-
Vertex Pharma (VRTX) Granted FDA Breakthrough Therapy Designation, EMA Priority Medicines Designation for VX-147
-
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
